Perrigo plummets on separation plan announcement

10 August 2018

Shares in Ireland-headquartered generic and OTC drugmaker Perrigo (NYSE: PRGO) closed 11% down on Thursday after plans were announced to separate the company's prescription pharmaceuticals business.

This comes after the previously-announced strategic portfolio review at a firm that is trying to reverse its fortunes following a punishing period that has seen its share price lose 65% of its value in the last three years.

In that time, the turbulence has included a price-fixing probe, multiple managerial changes, job losses and takeover rumors, and a year ago Perrigo announced that it was to sell its active pharmaceutical ingredients (API) business for $110 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK